What are the factors predicting progression to severe forms of COVID-19? One year into the pandemic, this question remains a key research subject, and one that scientists from Inserm and Université de Paris decided to explore further by studying the link between viral kinetics and disease progression.
The Phase 3 clinical trial of a COVID-19 vaccine is to be launched via Covireivac, a platform set up under the auspices of Inserm and the university hospitals to centralize COVID-19 vaccine trials in France. Janssen, the pharmaceutical division of the Johnson & Johnson group, has obtained the authorizations[1] needed for ENSEMBLE 2, a trial evaluating the efficacy and safety of vaccine candidate Ad26.COV2.S in the prevention of COVID-19...
Elderly women are currently at a higher risk than men of developing dementia, particularly Alzheimer's disease. A phenomenon that could partially be explained by inequalities in access to education between the sexes during the first half of the 20th century. Researchers from Inserm and Université de Paris, in collaboration with University College London, have shown that certain cognitive capacities have improved in women over recent generations, and that this...
As the COVID-19 pandemic continues, scientists are making significant headway in understanding the transmission of the SARS-CoV-2 coronavirus and the immune response it triggers at the time of infection. Researchers have provided new data on the very early stages of immune response.
The Discovery trial was originally launched in March 2020 by Inserm to evaluate possible treatments for Covid-19. On January 13th, 2021, the Discovery Europe trial Data Safety Monitoring Boards (DSMB) evaluated an interim report based on 776 patients of whom 389 received remdesivir and 387 received standard of care. The efficacy of the treatment was evaluated after 15 days and measured on the WHO-7-point ordinal scale. As a result...
Pour faire face à la pandémie de Covid-19, mieux comprendre le virus et accompagner la prise en charge des maladies, les scientifiques de l'Inserm sont plus que jamais mobilisés.
Endocrine disruptors can potentially become more harmful if mixed. Following on from research published in 2015, scientists continue to decipher the molecular mechanisms behind this phenomenon known as the "cocktail effect".
So-called "persistent" bacterial infections constitute a major public health problem and are linked to significant failures of antibiotic treatments. Researchers from Inserm and Université de Rennes 1, in collaboration with a team based in Switzerland, have identified a new mechanism to explain the persistence of Staphylococcus aureus.
A study by Inserm and Dijon University Hospital based on French nationwide data on around 130,000 patients hospitalized for either COVID-19 or seasonal influenza shows that the mortality rate among those admitted for COVID is three times higher than that of seasonal influenza.
A commonly used treatment in some forms of breast cancer, tamoxifen acts on the cancer cells by blocking the estrogen receptor (ER)a and thereby inhibiting their proliferation. However, the action of this drug appears to be more complex than that, with the addition of protective effects on the arteries that could reduce the risk of developing cardiovascular disease.
